Terence Flynn

Q: What is Terence Flynn's success rate?

Terence Flynn currently has a success rate of 85.58862726635019.

Q: What is the average return of Terence Flynn's calls?

Their stock ratings have generated an average return of 25.657479337816902.

Morgan Stanley | Healthcare

Terence Flynn is an analyst from Morgan Stanley specializing in the Healthcare sector. Ranked #1322 out of 4754 analysts, they have issued 59 stock ratings with a success rate of 85.59% and an average return of 25.66%.

Terence Flynn has a well-established track record, with 59 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 85.59% and an average return of 25.66%, underscoring their expertise and ability to identify winning opportunities for investors.

#1322

Out of 4754

Total Ratings

+85.59%

Success Rate

+25.66%

Average Return

Recent Ratings Analysis

MRK

Buy

Aug 20, 2026

Target

$179.00

Current

$152.22

Performance

—

Terence Flynn rated MRK as Overweight on Aug 20, 2026, setting a price target of 179. Shares have remained stable near 152.22, leaving the 179 target still in play.

NRIX

Buy

Jul 28, 2026

Target

$38.00

Current

$27.79

Performance

15.07%

On Jul 28, 2026, NRIX was given a Overweight rating by Terence Flynn, with a target price of 38. The stock rallied 15.07% after the rating, narrowing the gap to the target of 38 and validating the bullish stance.

JNJ

Buy

Jul 16, 2026

Target

$294.00

Current

$273.41

Performance

9.38%

JNJ received a Overweight rating from Terence Flynn on Jul 16, 2026, aiming for 294. Momentum has favored the Buy call, with shares climbing from 273.41 to 273.41, rewarding those who trusted the recommendation.

AMGN

Hold

Jul 08, 2026

Target

$333.00

Current

$442.36

Performance

20.21%

On Jul 08, 2026, Terence Flynn published a Equal-Weight outlook on AMGN, with a target of 333. The Hold call missed some of the bullish momentum as shares advanced toward 333.

LLY

Buy

Jul 08, 2026

Target

$1347.00

Current

$1280.74

Performance

5.34%

Terence Flynn on Jul 08, 2026 assigned LLY a Overweight rating, with a price target of 1347. The Buy call aligned well with market performance, producing a gain of 5.34%.

BNTX

Buy

Jul 08, 2026

Target

$119.00

Current

$113.12

Performance

20.95%

On Jul 08, 2026, Terence Flynn reaffirmed BNTX with a Overweight rating, targeting 119. The recommendation was supported by strong follow-through as the stock rose from 113.12 to 113.12.

BHVN

Buy

May 13, 2026

Target

$18.00

Current

$14.14

Performance

56.59%

BHVN was rated Overweight by Terence Flynn on May 13, 2026, with a price objective of 18. A bullish response from the market helped close the gap of 3.86 to the target.

RCUS

Hold

May 11, 2026

Target

$22.00

Current

$30.35

Performance

22.08%

On May 11, 2026, Terence Flynn initiated coverage on RCUS with a Equal-Weight rating and target of 22. The Hold stance underestimated the stock’s strength as it gained 22.08%.

VRTX

Buy

May 05, 2026

Target

$616.00

Current

$552.06

Performance

30.09%

Terence Flynn issued a Overweight recommendation for VRTX on May 05, 2026, price target set at 616. Investors following the Buy call captured upside momentum, with shares now at 552.06.

ABBV

Buy

Apr 30, 2026

Target

$278.00

Current

$265.97

Performance

25.86%

On Apr 30, 2026, ABBV was evaluated by Terence Flynn, who gave a Overweight rating and target of 278. This case illustrates how a timely bullish rating can translate into tangible gains of 25.86%.

NTLA

Hold

Apr 28, 2026

Target

$15.00

Current

$13.28

Performance

0.61%

Terence Flynn rated NTLA as Equal-Weight on Apr 28, 2026, setting a price target of 15. The Hold stance appears justified, as shares hovered around 13.28 with a 0.61% move.

UTHR

Hold

Apr 10, 2026

Target

$519.00

Current

$529.14

Performance

-7.45%

On Apr 10, 2026, UTHR was given a Equal-Weight rating by Terence Flynn, with a target price of 519. The rating provided protection from downside risk as the stock fell to 529.14.

RPRX

Buy

Apr 10, 2026

Target

$63.00

Current

$61.73

Performance

28.87%

RPRX received a Overweight rating from Terence Flynn on Apr 10, 2026, aiming for 63. Momentum has favored the Buy call, with shares climbing from 61.73 to 61.73, rewarding those who trusted the recommendation.

PFE

Hold

Apr 10, 2026

Target

$28.00

Current

$28.24

Performance

4.90%

On Apr 10, 2026, Terence Flynn published a Equal-Weight outlook on PFE, with a target of 28. Sideways action left the Hold view intact, with no major move since 28.24.

ALMS

Buy

Mar 20, 2026

Target

$38.00

Current

$23.99

Performance

-4.27%

Terence Flynn on Mar 20, 2026 assigned ALMS a Overweight rating, with a price target of 38. The recommendation remains pending validation as shares consolidate around 23.99.

BMY

Sell

Dec 12, 2025

Target

$37.00

Current

$67.61

Performance

29.00%

On Dec 12, 2025, Terence Flynn reaffirmed BMY with a Underweight rating, targeting 37. The Sell recommendation anticipated weakness, as shares dropped 29.00%.

GPCR

Buy

Dec 12, 2025

Target

$125.00

Current

$54.13

Performance

-19.28%

GPCR was rated Overweight by Terence Flynn on Dec 12, 2025, with a price objective of 125. This case shows how bullish projections can fail, with the stock now below 54.13.

OGN

Hold

Nov 11, 2025

Target

$9.00

Current

$13.73

Performance

82.58%

On Nov 11, 2025, Terence Flynn initiated coverage on OGN with a Equal-Weight rating and target of 9. The Hold stance underestimated the stock’s strength as it gained 82.58%.

ARVN

Hold

Mar 13, 2025

Target

$12.00

Current

$9.68

Performance

13.22%

Terence Flynn issued a Equal-Weight recommendation for ARVN on Mar 13, 2025, price target set at 12. A neutral call gave way to stronger-than-expected performance, closing in on 12.

CRSP

Sell

Feb 14, 2025

Target

$32.00

Current

$59.81

Performance

20.29%

On Feb 14, 2025, CRSP was evaluated by Terence Flynn, who gave a Underweight rating and target of 32. Investors benefited from heeding the Sell stance, avoiding a 20.29% decline.

BPMC

Buy

May 06, 2024

Target

$168.00

Current

$129.46

Performance

21.84%

Terence Flynn rated BPMC as Buy on May 06, 2024, setting a price target of 168. The call has proven timely, with shares rising 21.84% toward the price target of 168.

Frequency Asked Questions

Who is Terence Flynn?

Terence Flynn is an analyst from Morgan Stanley specializing in the Healthcare sector.

What is Terence Flynn's success rate?

Terence Flynn currently has a success rate of +85.59%.

How many ratings has Terence Flynn issued?

Terence Flynn has issued 59 stock ratings so far.

What is the average return of Terence Flynn's calls?

Their stock ratings have generated an average return of +25.66%.

What is Terence Flynn's ranking?

Terence Flynn is ranked #1322 out of 4754 analysts.

What types of ratings does Terence Flynn give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Terence Flynn?

You can follow Terence Flynn by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Terence Flynn?

Their latest rating was a Buy on MRK issued on 2026-08-20.